R

Redx Pharma PLC
LSE:REDX

Watchlist Manager
Redx Pharma PLC
LSE:REDX
Watchlist
Price: 15 GBX 31.58% Market Closed
Market Cap: 50.2m GBX

EV/EBITDA
Enterprise Value to EBITDA

-1.6
Current
-2.4
Median
13.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.6
=
Enterprise Value
49.1m GBX
/
EBITDA
-30m GBP
EBITDA Growth EV/EBITDA to Growth
UK
R
Redx Pharma PLC
LSE:REDX
Average EV/EBITDA: 437
Negative Multiple: -1.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.6
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-2.1
2-Years Forward
EV/EBITDA
-1.2
3-Years Forward
EV/EBITDA
N/A

See Also

Summary
REDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
REDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REDX stock valuation using valuation multiples.
Wall Street Estimates
REDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.